Effects of nanocurcumin supplementation on T‐helper 17 cells inflammatory response in patients with Behcet's disease: a randomized controlled trial. (4th March 2022)

• Record Type: Journal Article
• Authors: Farzaneh, Rojin; Khabbazi, Alireza; Soltani-Zangbar, Mohammad Sadegh; Abbasian, Samaneh; Malek Mahdavi, Aida; Motavalli, Roza; Yousefi, Mehdi
• Is Part Of: Immunopharmacology and immunotoxicology. Volume 44:Number 2(2022)
• Page Start: 206
• Page End: 215
• Publication Date: 2022-03-04
• Subjects: Behçet's disease -- nanocurcumin -- T‐helper 17 cells -- proinflammatory cytokines -- microRNA; Immunopharmacology -- Periodicals; Immunotoxicology -- Periodicals; Antibody-toxin conjugates -- Periodicals; Immunology -- Periodicals; 615.37
• DOI: 10.1080/08923973.2022.2026380
• Languages: English
• ISSNs: 0892-3973

Abstract

Abstract: Objective: Present research was performed to assess the effects of nanocurcumin supplementation on T‐helper 17 (Th17) cells inflammatory response in patients with Behcet's disease (BD). Methods: In this randomized double-blind, placebo-controlled trial, 36 BD subjects were randomly placed into two groups to take 80 mg/day nanocurcumin or placebo for eight weeks. Disease activity, frequency of Th17 cells and expression of related parameters including retinoic acid‐related orphan receptor γ (RORγt) transcription factor messenger RNA (mRNA), related microRNAs (miRNAs) such as miRNA-155, miRNA-181, and miRNA-326 as well as proinflammatory cytokines including interleukin (IL)‐17 and IL‐23 were evaluated. Results: Thirty-two patients (17 in the nanocurcumin and 15 in the placebo groups) completed the trial. Number of Th17 cells decreased significantly in the nanocurcumin group compared to baseline ( p = .012) and placebo ( p = .047). Moreover, RORγt, IL‐17, IL‐23, miRNA-155, miRNA-181, and miRNA-326 mRNA expression decreased significantly in the nanocurcumin group compared with baseline ( p = .004, p = .009, p < .001, p < .001, p < .001, p < .001, respectively) and placebo ( p = .002, p = .021, p = .006, p = .035, p < .001, p = .017, respectively). Significant reductions in IL-17 and IL-23 were seen in nanocurcumin group compared with baseline ( p = .017 and p = .015) and placebo ( p = .047 and p = .048, respectively). Significant reduction in disease activity was observed in nanocurcumin group compared with placebo group ( p = .035). Conclusion: Nanocurcumin supplementation had favorable effects in improving inflammatory factors and disease activity in BD patients. Additional studies are warranted to suggest nanocurcumin as a safe complementary therapy in BD. Highlights: Nanocurcumin supplementation decreased Th17 cells frequency significantly compared with baseline and placebo group. Nanocurcumin supplementation decreased mRNA expression of RORγt, IL‐17, IL‐23, miRNA-155, miRNA-181, and miRNA-326 significantly compared to baseline and placebo group. Nanocurcumin supplementation decreased cell supernatant IL-17 and IL-23 significantly compared to baseline and placebo group. Nanocurcumin supplementation decreased disease activity significantly compared to placebo group.